Animal Health USA 2020 | Kisaco Research

Animal Health Investment USA

Serving Unmet Medical Needs in Veterinary Medicine Through Business Partnering and Investment

Download Agenda
Virtual Event
12-13 October, 2020

“I had strong expectations for the conference, and they were far exceeded. The quality of the connections I made and the information learned will strengthen our company and help us succeed.”

Peter Alberti, CEO, Pet Cause Media

Why Attend

Animal Health Investment USA is the premier investment forum showcasing the most exciting partner opportunities in animal health and connecting those businesses together with financial investors and strategic corporate partners.


This year, in light of Covid-19, our event is now a virtual one. We appreciate that this will be a new experience for many of you but operating virtually is now the new business norm, at least for now, and we look forward to working with you to make this a truly effective experience.


For the discussions this year, we will be looking specifically at maximizing the therapeutic and commercial potential of human technologies and serving unmet medical needs in veterinary health. Additionally, we continue to be focused on driving investor engagement and showcasing the industry’s most exciting emerging companies.


We have keynote presentations and C-level panel discussions that address the trends and market dynamics of the animal health industry, across all species. A key element of the investment forum is our virtual, private meeting scheduler, available to all participants.

300+
Attendees
40+
Investors
80+
Start-ups
25+
Private Meetings per person

The Virtual Experience

Top 10 benefits

- Tailor Your Agenda 

- More Audience Participation

- Improved Audience Visibility 

- On-Demand Content

- High Quality Speakers 

- More Networking Opportunities 

- Save Time & Money 

- Increased Content 

- More insights 

- Business Development Opportunities - Talk to our team to find out out more [email protected].

Platform Preview

Animal Health has distinct advantages over human healthcare:

  1. The research and development process for animal health products is typically shorter and less expensive than for human therapeutics, as animal trials typically can be performed in the target species at an earlier stage, and shorter lifespans result in faster safety assessment and trial completion.
  2. A substantial portion of animal health R&D is focused on product life-cycle management as opposed to novel drugs, which also leads to less risky pipelines.
  3. Animal health medicines and vaccines face lower pressure from generic competition when compared to human healthcare peers.
  4. Animal health is primarily a cash business and does not face the same insurance/third party payer and drug pricing risks that can be an overhang on human therapeutics.

Speakers

 

Michael Helmstetter

Founder, President and CEO
TechAccel, LLC

Dr. Michael Helmstetter is Co-Founder, President, and Chief Executive Officer of TechAccel LLC (Technology Acceleration Partners).

TechAccel is a technology and venture development company in the agriculture and animal health sectors. The company invests in or acquires new technology and funds science advancement programs with research university partners to assist in commercialization.

Michael Helmstetter

Founder, President and CEO
TechAccel, LLC

Michael Helmstetter

Founder, President and CEO
TechAccel, LLC

Dr. Michael Helmstetter is Co-Founder, President, and Chief Executive Officer of TechAccel LLC (Technology Acceleration Partners).

TechAccel is a technology and venture development company in the agriculture and animal health sectors. The company invests in or acquires new technology and funds science advancement programs with research university partners to assist in commercialization.

Michael also serves as Managing Partner of Covenant Animal Health Partners, a TechAccel subsidiary that focuses on development of “revenue-ready” animal health products for both companion and farm animals.

Before founding TechAccel, Michael served as the fifth President and Chief Executive Officer of MRIGlobal – one of the nation's most prominent research institutions. In his 14 years with MRIGlobal (formerly Midwest Research Institute), he led its growth from 2 to 17 national and international locations.

Michael has more than 30 years of experience working with the private sector and government agencies, including laboratory management positions at Applied Marine Research Laboratory in Norfolk, Va., and program management for the Harbor Branch Oceanographic Institution in Fort Pierce, Fla. He was President and Chairman of startup Brevard Teaching and Research Laboratories, a post he held until the company was acquired by MRIGlobal.

Michael received a Ph.D. in Chemical Toxicology/Oceanography from Old Dominion University and a B.S. in Biology from Allegheny College. He has been a panelist, keynote speaker, lecturer, reviewer to several journals, and is the author of numerous publications, articles, book chapters, and technical reports.

He has served on several boards, including Labconco Corp. Board of Directors and University of Missouri-Kansas City Board of Trustees, as well as numerous civic organizations. He is a contributing opinion writer for Forbes.com.

Michael lives in suburban Kansas City.

Email: [email protected]
LinkedIn www.linkedin.com/in/michaelhelmstetter/

 

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC

Spencer Swayze

Managing Director
Paine Schwartz Partners, LLC
 

Kristin Bloink

Vice President, Global Research & External Innovation
Elanco Animal Health

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

Kristin Bloink

Vice President, Global Research & External Innovation
Elanco Animal Health

Kristin Bloink

Vice President, Global Research & External Innovation
Elanco Animal Health

Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D.   She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector.  She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.   

 

Linda Rhodes

Independent Animal Health Expert

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Linda Rhodes

Independent Animal Health Expert

Linda Rhodes

Independent Animal Health Expert

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

 

Phil Austin

Founding Partner
Anterra Capital

Phil Austin

Founding Partner
Anterra Capital

Phil Austin

Founding Partner
Anterra Capital
 

Michael Rohlfsen

Vice President, Business Development
TechAccel, LLC

Michael Rohlfsen

Vice President, Business Development
TechAccel, LLC

Michael Rohlfsen

Vice President, Business Development
TechAccel, LLC
 

Daniel Promislow

Dog Aging Project Co-Director
U19 Principal Investigator

Daniel Promislow

Dog Aging Project Co-Director
U19 Principal Investigator

Daniel Promislow

Dog Aging Project Co-Director
U19 Principal Investigator
 

Ashley Kalinauskus

Founder and CEO
Torigen, Inc.

Ashley Kalinauskus

Founder and CEO
Torigen, Inc.

Ashley Kalinauskus

Founder and CEO
Torigen, Inc.
 

Wesley Wierson

Founder & CEO
LEAH Labs

Wesley Wierson

Founder & CEO
LEAH Labs

Wesley Wierson

Founder & CEO
LEAH Labs
 

Dottie Brown

Senior Research Advisor, Translational Comparative Medical Research
Elanco

Dottie Brown

Senior Research Advisor, Translational Comparative Medical Research
Elanco

Dottie Brown

Senior Research Advisor, Translational Comparative Medical Research
Elanco
 

Bruce Taillon

Director External Innovation
Elanco

Bruce Taillon

Director External Innovation
Elanco

Bruce Taillon

Director External Innovation
Elanco
 

Wendy Vaala

Director of Scientific Marketing Affairs
Merck Animal Health

Wendy Vaala

Director of Scientific Marketing Affairs
Merck Animal Health

Wendy Vaala

Director of Scientific Marketing Affairs
Merck Animal Health
 

Fabian Kausche

Chairman
Stonehaven Incubate

Fabian Kausche

Chairman
Stonehaven Incubate

Fabian Kausche

Chairman
Stonehaven Incubate
 

Brian Axe

Principal
NovaQuest Capital Management

Brian Axe

Principal
NovaQuest Capital Management

Brian Axe

Principal
NovaQuest Capital Management
 

Matthew Salois

Chief Economist
AVMA

Matthew Salois

Chief Economist
AVMA

Matthew Salois

Chief Economist
AVMA
 

John Butler

CEO
The Beef Marketing Group

John Butler

CEO
The Beef Marketing Group

John Butler

CEO
The Beef Marketing Group
 

Kate E. Creevy

DVM, MS, DACVIM, Chief Veterinary Officer
The Dog Aging Project

Kate E. Creevy

DVM, MS, DACVIM, Chief Veterinary Officer
The Dog Aging Project

Kate E. Creevy

DVM, MS, DACVIM, Chief Veterinary Officer
The Dog Aging Project
 

Rimma Driscoll

Senior Vice President, Global Business Development
Zoetis

Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure.

Rimma Driscoll

Senior Vice President, Global Business Development
Zoetis

Rimma Driscoll

Senior Vice President, Global Business Development
Zoetis

Rimma Driscoll is an executive in Global Business Development and Strategic Alliances with 20+ years in the field. Rimma has a depth of experience in a broad range of global transactions including JVs,Strategic Alliances, Collaborations, Acquisitions, Divestitures, Licensing Deals, and Partnerships. This experience span from small Discovery deals to multi-billionaire dollar divestitures. Rimma guides Multi-function teams on the external strategies and then leads all aspects of negotiations, and leverages external relationships to bring transactions to closure. She has worked extensively in Pharmaceuticals, Consumer Healthcare and Consumer Products businesses.

 

Scott Brown

VP External Innovation, Veterinary Medicine R&D
Zoetis

Scott Brown

VP External Innovation, Veterinary Medicine R&D
Zoetis

Scott Brown

VP External Innovation, Veterinary Medicine R&D
Zoetis
 

Janet Patterson-Kane

Chief Scientific Officer
Morris Animal Foundation

Janet Patterson-Kane

Chief Scientific Officer
Morris Animal Foundation

Janet Patterson-Kane

Chief Scientific Officer
Morris Animal Foundation
 

Michelle Haven

Senior Advisor & Venture Partner
Anterra Capital

Michelle Haven

Senior Advisor & Venture Partner
Anterra Capital

Michelle Haven

Senior Advisor & Venture Partner
Anterra Capital
 

Juergen Horn

Senior Advisor & Venture Partner
Anterra Capital, Founder & CEO at Invetx

Juergen Horn

Senior Advisor & Venture Partner
Anterra Capital, Founder & CEO at Invetx

Juergen Horn

Senior Advisor & Venture Partner
Anterra Capital, Founder & CEO at Invetx
 

Randolph Seidler

VP, Global Head of Business Development Animal
Boehringer Ingelheim

Randolph Seidler

VP, Global Head of Business Development Animal
Boehringer Ingelheim

Randolph Seidler

VP, Global Head of Business Development Animal
Boehringer Ingelheim
 

Michael Williams

Professor of Practice
UNC-NCSU Joint Department of Biomedical Engineering & Research Affiliate, Massachusetts Institute of Technology

Michael Williams

Professor of Practice
UNC-NCSU Joint Department of Biomedical Engineering & Research Affiliate, Massachusetts Institute of Technology

Michael Williams

Professor of Practice
UNC-NCSU Joint Department of Biomedical Engineering & Research Affiliate, Massachusetts Institute of Technology

Partners

Headline Partner

Associate Partners

Start-Up Development Partner

Event Partners

Media Partners

The Agenda

You can download our latest agenda here.

Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.

Download Agenda

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Saturday, September 19, 2020 to Wednesday, October 14, 2020
Tier 1
$899
Standard rate after 18 September
Pre-revenue companies
Human Biotechs
Academics
Charities
Angel and Venture Capital Investors
Please note: Service providers do not qualify for this rate
Friday, September 18, 2020 to Wednesday, October 14, 2020
Tier 2
$1,899
Standard rate after 18 September
CROs & CMOs
Consultants, M&A Advisors
Private Equity Investors & Brokers
Start-Up Incubators & Accelerators
Pharmaceutical Companies
Animal Health Companies
To increase your brand presence, contact Stephen: [email protected]
Preparing registration...
Payment Terms for Animal Health Investment Europe:
  • Please note that a $70 processing fee will apply to any invoices requested.
  • Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
  • All Prices are in USD
  • All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
  • No discounts or offers can be combined.
  • Please view our Cancellation Policy.
  • Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
  • Please Note: No additional discounts are available on ‘Emerging Company’ pricing.

Global Advisory Board

Author:

Marc Prikazsky

Chairman and Chief Executive Officer
CEVA Santé Animale S.A

Author:

Mr. Rob Kelly

Executive Vice President International Operations
Zoetis Inc.

Author:

Aaron Schacht

Executive Vice President - Innovation, Regulatory & Business Development
Elanco

Mr. Aaron Schacht is currently the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Health. Prior to this, Mr. Aaron Schacht held a role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.

Author:

Sébastien Huron

Chairman of the Executive Board
Virbac Santé Animale

Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.

Author:

Jean-Luc Michel

Head of Global Strategic Marketing
Boehringer Ingelheim

After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.

In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.

After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.

Author:

Kathy V. Turner

Corporate Vice President and Global Chief Marketing Officer
IDEXX

Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

Author:

George Gunn

Founder and CEO
Stonehaven Consulting AG

Author:

Linda Rhodes

Independent Animal Health Expert

Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.

Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.

Author:

Alan Mackay

Executive Partner and Founder
GHO Capital

Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.

Author:

Dave Ross

Chief Executive Officer
Agri-EPI Centre Ltd

Become a Sponsor

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Other events you might be interested in:

Animal Health LatAm 2020

Animal Health Asia 2020

AH Europe 2021